{"id":"vidarabine","rwe":[],"tags":[{"label":"vidarabine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Dipeptidyl peptidase 4","category":"target"},{"label":"DPP4","category":"gene"},{"label":"POLA1","category":"gene"},{"label":"DCK","category":"gene"},{"label":"J05AB03","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Herpes simplex dendritic keratitis","category":"indication"},{"label":"Herpes simplex keratitis","category":"indication"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=VIDARABINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:00:42.412491+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Vidarabine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:00:51.021574+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:00:49.401623+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VIDARABINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:00:50.258587+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL16720/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:00:50.776087+00:00"}},"allNames":"vidarabin","offLabel":[],"synonyms":["vidarabine anhydrous","vidarabine","adenine arabinoside","araadenosine","arabinosyladenine","vidarabin"],"timeline":[{"date":"1976-11-26","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1976-11-26","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Vidarabin","ecosystem":[{"indication":"Herpes simplex dendritic keratitis","otherDrugs":[{"name":"ganciclovir","slug":"ganciclovir","company":"Roche Palo"}],"globalPrevalence":491500000},{"indication":"Herpes simplex keratitis","otherDrugs":[{"name":"idoxuridine","slug":"idoxuridine","company":"Allergan"},{"name":"trifluridine","slug":"trifluridine","company":"Monarch Pharms"}],"globalPrevalence":491500000}],"mechanism":{"target":"Dipeptidyl peptidase 4","novelty":"Follow-on","targets":[{"gene":"DPP4","source":"DrugCentral","target":"Dipeptidyl peptidase 4","protein":"Dipeptidyl peptidase 4"},{"gene":"POLA1","source":"DrugCentral","target":"DNA polymerase alpha catalytic subunit","protein":"DNA polymerase alpha catalytic subunit"},{"gene":"DCK","source":"DrugCentral","target":"Deoxycytidine kinase","protein":"Deoxycytidine kinase"},{"gene":"DGUOK","source":"DrugCentral","target":"Deoxyguanosine kinase, mitochondrial","protein":"Deoxyguanosine kinase, mitochondrial"},{"gene":"RRM1","source":"DrugCentral","target":"Ribonucleoside-diphosphate reductase large subunit","protein":"Ribonucleoside-diphosphate reductase large subunit"},{"gene":"RRM2","source":"DrugCentral","target":"Ribonucleoside-diphosphate reductase subunit M2","protein":"Ribonucleoside-diphosphate reductase subunit M2"},{"gene":"PRPS1","source":"DrugCentral","target":"Ribose-phosphate pyrophosphokinase 1","protein":"Ribose-phosphate pyrophosphokinase 1"}],"modality":"Small Molecule","drugClass":"vidarabine","explanation":"","oneSentence":"","technicalDetail":"Vidarabine exerts its antiviral effects by inhibiting viral DNA synthesis, specifically through the inhibition of viral DNA polymerase, which is essential for viral replication."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Vidarabine","title":"Vidarabine","extract":"Vidarabine or 9-β-D-arabinofuranosyladenine (ara-A) is an antiviral drug which is active against herpes simplex and varicella zoster viruses."},"commercial":{"launchDate":"1976","_launchSource":"DrugCentral (FDA 1976-11-26, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2818","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=VIDARABINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=VIDARABINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Vidarabine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:08:54.773229","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:00:58.319499+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"acyclovir","drugSlug":"acyclovir","fdaApproval":"1982-03-29","patentExpiry":"Mar 23, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"idoxuridine","drugSlug":"idoxuridine","fdaApproval":"1963-06-11","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ganciclovir","drugSlug":"ganciclovir","fdaApproval":"1989-06-23","patentExpiry":"Sep 2, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"famciclovir","drugSlug":"famciclovir","fdaApproval":"1994-06-29","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valaciclovir","drugSlug":"valaciclovir","fdaApproval":"1995-06-23","relationship":"same-class"},{"drugName":"cidofovir","drugSlug":"cidofovir","fdaApproval":"1996-06-26","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"penciclovir","drugSlug":"penciclovir","fdaApproval":"1996-09-24","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"valganciclovir","drugSlug":"valganciclovir","fdaApproval":"2001-03-29","patentExpiry":"Dec 11, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"remdesivir","drugSlug":"remdesivir","fdaApproval":"2020-10-22","patentExpiry":"Sep 6, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"vidarabine","indications":{"approved":[{"name":"Herpes simplex dendritic keratitis","source":"DrugCentral","snomedId":29943008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":491500000,"prevalenceMethod":"curated","prevalenceSource":"Bull World Health Organ, 2016 (PMID:32514197)"},{"name":"Herpes simplex keratitis","source":"DrugCentral","snomedId":9389005,"regulator":"FDA","usPrevalence":null,"globalPrevalence":491500000,"prevalenceMethod":"curated","prevalenceSource":"Bull World Health Organ, 2016 (PMID:32514197)"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"acyclovir","brandName":"acyclovir","genericName":"acyclovir","approvalYear":"1982","relationship":"same-class"},{"drugId":"idoxuridine","brandName":"idoxuridine","genericName":"idoxuridine","approvalYear":"1963","relationship":"same-class"},{"drugId":"ganciclovir","brandName":"ganciclovir","genericName":"ganciclovir","approvalYear":"1989","relationship":"same-class"},{"drugId":"famciclovir","brandName":"famciclovir","genericName":"famciclovir","approvalYear":"1994","relationship":"same-class"},{"drugId":"valaciclovir","brandName":"valaciclovir","genericName":"valaciclovir","approvalYear":"1995","relationship":"same-class"},{"drugId":"cidofovir","brandName":"cidofovir","genericName":"cidofovir","approvalYear":"1996","relationship":"same-class"},{"drugId":"penciclovir","brandName":"penciclovir","genericName":"penciclovir","approvalYear":"1996","relationship":"same-class"},{"drugId":"valganciclovir","brandName":"valganciclovir","genericName":"valganciclovir","approvalYear":"2001","relationship":"same-class"},{"drugId":"remdesivir","brandName":"remdesivir","genericName":"remdesivir","approvalYear":"2020","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05400109","phase":"PHASE1","title":"Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Wald","startDate":"2023-04-26","conditions":["Non Hodgkin Lymphoma"],"enrollment":21,"completionDate":"2026-04-01"},{"nctId":"NCT05757310","phase":"PHASE1","title":"A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2024-11-15","conditions":["Recurrent Severe Aplastic Anemia","Refractory Severe Aplastic Anemia"],"enrollment":6,"completionDate":"2027-06-18"},{"nctId":"NCT04083183","phase":"PHASE1,PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":["Non-Malignant Neoplasm"],"enrollment":40,"completionDate":"2028-01-09"},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":["Colorectal Cancer","Hematologic Malignancy","Rectum Cancer","Acute Myeloid Leukemia","Myelodysplastic Syndromes","Acute Lymphoblastic Leukemia","Chronic Myeloid Leukemia","Chronic Lymphocytic Leukemia","Hodgkin Lymphoma","Non Hodgkin Lymphoma","Myeloproliferative Syndrome","Plasma Cell Myeloma","Gastric Cancer","Esophageal Cancer","Esophagus Cancer","Gastric Cancer, Metastatic","Unresectable Esophageal Cancer","Metastatic Esophageal Cancer"],"enrollment":12,"completionDate":"2026-06-01"},{"nctId":"NCT05031897","phase":"PHASE2","title":"Two Step Haplo With Radiation Conditioning","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-10-25","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Adult T-Cell Leukemia/Lymphoma","Aplastic Anemia","Chronic Lymphocytic Leukemia","Chronic Myeloid Leukemia, BCR-ABL1 Positive","Chronic Myelomonocytic Leukemia","Essential Thrombocythemia","Hematopoietic and Lymphatic System Neoplasm","Hodgkin Lymphoma","Multiple Myeloma","Myelodysplastic Syndrome","Myelofibrosis","Myeloid Neoplasm","Non-Hodgkin Lymphoma","Polycythemia Vera","Small Lymphocytic Lymphoma"],"enrollment":63,"completionDate":"2032-04"},{"nctId":"NCT03779854","phase":"PHASE2","title":"Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2019-08-29","conditions":["Acute Biphenotypic Leukemia","Acute Leukemia","Acute Leukemia of Ambiguous Lineage","Acute Lymphoblastic Leukemia","Acute Undifferentiated Leukemia","Allogeneic Hematopoietic Stem Cell Transplantation Recipient","Blastic Plasmacytoid Dendritic Cell Neoplasm","Blasts Under 25 Percent of Bone Marrow Nucleated Cells","Blasts Under 5 Percent of Bone Marrow Nucleated Cells","Mixed Phenotype Acute Leukemia","Myelodysplastic Syndrome With Excess Blasts-1","Myelodysplastic Syndrome/Acute Myeloid Leukemia","Burkitt Leukemia","Chronic Monocytic Leukemia","Lymphoblastic Lymphoma","Mast Cell Leukemia","Myeloproliferative Neoplasm"],"enrollment":68,"completionDate":"2027-12-31"},{"nctId":"NCT05618925","phase":"PHASE1","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-08-22","conditions":["Non Hodgkin's Lymphoma Refractory/Relapsed"],"enrollment":20,"completionDate":"2027-03-15"},{"nctId":"NCT04083170","phase":"PHASE2","title":"Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-10-06","conditions":["Acute Erythroid Leukemia","Acute Lymphoblastic Leukemia","Acute Megakaryoblastic Leukemia","Acute Myeloid Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Hematopoietic and Lymphoid Cell Neoplasm","HIV Infection","Myelodysplastic Syndrome","Myelodysplastic Syndrome With Excess Blasts","Non-Hodgkin Lymphoma","Refractory Anemia"],"enrollment":1,"completionDate":"2022-11-30"},{"nctId":"NCT02085408","phase":"PHASE3","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-04","conditions":["Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Megakaryoblastic Leukemia (M7)","Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","Adult Acute Monoblastic Leukemia (M5a)","Adult Acute Monocytic Leukemia (M5b)","Adult Acute Myeloblastic Leukemia With Maturation (M2)","Adult Acute Myeloblastic Leukemia Without Maturation (M1)","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","Adult Acute Myelomonocytic Leukemia (M4)","Adult Erythroleukemia (M6a)","Adult Pure Erythroid Leukemia (M6b)","Secondary Acute Myeloid Leukemia","Untreated Adult Acute Myeloid Leukemia"],"enrollment":727,"completionDate":"2022-12-21"},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":["Lymphoblastic Lymphoma"],"enrollment":23,"completionDate":"2022-05-31"},{"nctId":"NCT00000985","phase":"PHASE3","title":"Comparison of Foscarnet Versus Vidarabine in the Treatment of Herpes Infection in Patients With AIDS Who Have Not Had Success With Acyclovir","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Herpes Simplex","HIV Infections"],"enrollment":26,"completionDate":"1990-10"},{"nctId":"NCT01158885","phase":"PHASE2","title":"Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08","conditions":["Minimal Residual Disease","Leukemia, Lymphoblastic, Acute","Leukemia, Myelogenous, Acute"],"enrollment":2,"completionDate":"2012-10-24"},{"nctId":"NCT02724163","phase":"PHASE3","title":"International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2016-04","conditions":["Acute Myeloid Leukaemia"],"enrollment":700,"completionDate":"2032-12"},{"nctId":"NCT01434472","phase":"PHASE2","title":"High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-11-16","conditions":["Post-Transplant Lymphoproliferative Disorder","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Burkitt Lymphoma","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Burkitt Lymphoma","Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":20,"completionDate":"2020-05-06"},{"nctId":"NCT02750254","phase":"PHASE1","title":"Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2016-06-27","conditions":["Acute Myeloid Leukemia","Myelodysplastic Syndrome","Acute Lymphocytic Leukemia"],"enrollment":5,"completionDate":"2020-10-14"},{"nctId":"NCT02925351","phase":"EARLY_PHASE1","title":"Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases","status":"COMPLETED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2016-01-25","conditions":["Autoimmune Disease","Crohn Disease","Inflammatory Disorder","Rheumatoid Arthritis","Systemic Lupus Erythematosus","Takayasu Arteritis"],"enrollment":8,"completionDate":"2018-04-30"},{"nctId":"NCT02888301","phase":"","title":"18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2015-06-12","conditions":["Malignant Neoplasm"],"enrollment":12,"completionDate":"2018-04-30"},{"nctId":"NCT00096161","phase":"PHASE2","title":"Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2003-05","conditions":["Acute Lymphoblastic Leukemia","Acute Myeloid Leukemia","Chronic Lymphocytic Leukemia","Chronic Myelogenous Leukemia, BCR-ABL1 Positive","Graft Versus Host Disease","Hodgkin Lymphoma","Myelodysplastic/Myeloproliferative Neoplasm","Non-Hodgkin Lymphoma","Plasma Cell Myeloma","Waldenstrom Macroglobulinemia"],"enrollment":36,"completionDate":"2015-08"},{"nctId":"NCT03935347","phase":"PHASE2","title":"Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy","status":"WITHDRAWN","sponsor":"Roswell Park Cancer Institute","startDate":"2019-06-20","conditions":["Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Unresectable Renal Pelvis Urothelial Carcinoma","Unresectable Ureter Urothelial Carcinoma"],"enrollment":0,"completionDate":"2023-05-01"},{"nctId":"NCT02057770","phase":"PHASE1","title":"Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2014-02-28","conditions":["Leukemia, Myeloid, Acute"],"enrollment":25,"completionDate":"2018-03-23"},{"nctId":"NCT01024010","phase":"PHASE2","title":"Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2010-03","conditions":["Chronic Lymphocytic Leukemia","Stage 0 Chronic Lymphocytic Leukemia","Stage I Chronic Lymphocytic Leukemia","Stage I Small Lymphocytic Lymphoma","Stage II Chronic Lymphocytic Leukemia","Stage II Small Lymphocytic Lymphoma","Stage III Chronic Lymphocytic Leukemia","Stage III Small Lymphocytic Lymphoma","Stage IV Chronic Lymphocytic Leukemia","Stage IV Small Lymphocytic Lymphoma"],"enrollment":82,"completionDate":"2017-09-28"},{"nctId":"NCT00245037","phase":"PHASE1,PHASE2","title":"Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2005-06","conditions":["Chronic Myeloproliferative Disorders","Leukemia","Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic/Myeloproliferative Neoplasms","Precancerous Condition"],"enrollment":147,"completionDate":"2015-08"},{"nctId":"NCT00372619","phase":"PHASE1,PHASE2","title":"Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":["Leukemia"],"enrollment":74,"completionDate":"2012-08"},{"nctId":"NCT00708721","phase":"PHASE1,PHASE2","title":"Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia","status":"TERMINATED","sponsor":"University of Utah","startDate":"2008-03","conditions":["Cancer","Chronic Myelomonocytic Leukemia"],"enrollment":11,"completionDate":"2014-11"},{"nctId":"NCT01621477","phase":"PHASE2","title":"T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08","conditions":["Acute Lymphoblastic Leukemia","Acute Myelocytic Leukemia","Chronic Myelocytic Leukemia","Juvenile Myelomonocytic Leukemia","Myelodysplastic Syndrome","Hodgkin or Non-Hodgkin Lymphoma","Sarcoma, Myeloid"],"enrollment":34,"completionDate":"2015-12"},{"nctId":"NCT02447055","phase":"EARLY_PHASE1","title":"Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2015-12","conditions":["Multiple Myeloma","Myeloma-Multiple"],"enrollment":0,"completionDate":"2016-06"},{"nctId":"NCT01065545","phase":"PHASE1","title":"The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2011-06","conditions":["Acute Myeloid Leukemia"],"enrollment":0,"completionDate":""},{"nctId":"NCT00028418","phase":"PHASE1","title":"Clofarabine in Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"1999-02","conditions":["Hematologic Neoplasms","Lymphoproliferative Disorders","Leukemia","Leukemia, Lymphocytic, Chronic"],"enrollment":100,"completionDate":"2004-03"},{"nctId":"NCT00338494","phase":"PHASE1","title":"Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma","status":"COMPLETED","sponsor":"Yale University","startDate":"2005-10","conditions":["B-Cell Lymphoma"],"enrollment":16,"completionDate":"2011-04"},{"nctId":"NCT00795132","phase":"PHASE2","title":"Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"University of Utah","startDate":"2004-04","conditions":["Acute Leukaemia","Chronic Disease","Leukemia","Myelodysplasia","Lymphoma"],"enrollment":47,"completionDate":"2009-07"},{"nctId":"NCT00334074","phase":"PHASE2","title":"Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2005-08","conditions":["Acute Myelogenous Leukemia","Myelodysplastic Syndromes","Chronic Myelogenous Leukemia"],"enrollment":30,"completionDate":"2008-02"},{"nctId":"NCT00852163","phase":"PHASE2","title":"Study of Stem Cell Transplant for Leukemia and Myelodysplastic Syndromes Using Clofarabine and Busulfan Regimen","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2007-03","conditions":["Leukemia","Myelodysplastic Syndrome"],"enrollment":20,"completionDate":"2011-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146963","MMSL":"5673","NDDF":"003014","UNII":"FA2DM6879K","VUID":"4018650","CHEBI":"CHEBI:45327","VANDF":"4018650","INN_ID":"2842","RXNORM":"11194","UMLSCUI":"C0042646","chemblId":"CHEMBL16720","ChEMBL_ID":"CHEMBL1090","KEGG_DRUG":"D00406","DRUGBANK_ID":"DB00194","PDB_CHEM_ID":"RAB","PUBCHEM_CID":"21704","SNOMEDCT_US":"37306000","IUPHAR_LIGAND_ID":"4806","SECONDARY_CAS_RN":"24356-66-9","MESH_DESCRIPTOR_UI":"D014740"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"0%"},"publicationCount":540,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AB03","allCodes":["J05AB03","S01AD06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1976","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1976-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1976-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1976-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1976-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1976-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1976-11-26T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:00:58.319499+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}